Reports Q3 revenue $3.079M, consensus $3.08M. “We have taken critical steps in advancing our pipeline, including the positive data and successful outcome of our recent FDA meeting regarding our LCA5 program and the opening of recruitment in our BEST1 Phase 1/2 clinical trial,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics (IRD). “We look forward to continuing this momentum into next year, when we expect multiple data readouts across several programs. The financing we recently completed reinforces the strong support from existing shareholders and new prominent healthcare investors and provides us with financial resources to expedite the path toward multiple approvals.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics Announces $23M Direct Offering
- Positive Outlook for Opus Genetics: Regulatory Support and Financial Stability Justify Buy Rating
- Opus Genetics Announces $23 Million Direct Offering
- Opus Genetics announces $23M registered direct offering
- Opus Genetics announces completion of Type B RMAT meeting with FDA